# Integrating liquid biopsy and mutational signatures to advance precision oncology

## TL;DR

This review explores how combining liquid biopsy and mutational signatures can improve cancer treatment by tracking tumor changes over time.

## Contribution

The paper introduces a novel framework integrating liquid biopsy and mutational signatures to enhance precision oncology.

## Key findings

- Liquid biopsy and mutational signatures can track tumor evolution over time.
- The combination improves cancer screening and personalized treatment strategies.

## Abstract

The effective application of precision oncology in solid tumors remains challenging due to genetic heterogeneity and the absence of actionable alterations in some cancers. In this review, we discuss the integration of liquid biopsy and mutational signatures as a potential framework to address these limitations by enabling longitudinal detection of mutational processes that arise during tumor development and evolution. Together, these complementary approaches hold substantial promise for enhancing cancer screening, refining diagnosis, and guiding personalized therapeutic strategies, thereby advancing the field of precision oncology.